

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form PTO-1449

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT'S****Complete if Known**

Application Number	10/618,134
Filing Date:	July 11, 2003
First Named Inventor	Gerold SCHULER et al
Art Unit	1644
Examiner Name:	Sanjoo Jalla
Attorney Docket Number:	100725-37 / Kreiser 1108 KGB

Sheet 1

of 1

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A	US - 6,803,036 B1	10-12-2004	Horwitz	

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No.	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	B	WO 93 02108 A	02-04-1993	IDEC Pharma Corp		
	C	WO 98 56417 A	12-17-1998	US Navy Dept.		
	D	WO 00 42856	07-27-2000	Schepens Eye Inst.		
	E	EP 1 409 650 B1	04-12-2006	Fondazione Telethon		
	F	WO 02 097070	12-05-2002	Fondazione Centro San Raffaele Del Monte Tabor		

**NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>7</sup>
	G	De JONG et al., "Differential effect of transforming growth factor-β1 on the activation of human naïve and memory CD4 <sup>+</sup> T lymphocytes," <i>International Immunology</i> , Vol. 6, No. 4, pp. 631-638 (January 1994)	
	H	JONULEIT et al., "Induction of Interleukin 10-producing, Nonproliferating CD4 <sup>+</sup> T Cells with Regulatory Properties by Repetitive Stimulation with Allogeneic Immature Human Dendritic Cells," <i>J. Exp. Med.</i> , Vol. 192, No. 9, pp. 1213-1222 (November 6, 2000).	
	I	SHIMIZU et al., "Induction of Tumor Immunity by Removing CD25 <sup>+</sup> CD4 <sup>+</sup> T Cells: A Common Basis Between Tumor Immunity and Autoimmunity," <i>J. Immunol.</i> , Vol. 163, No. 10, pp. 5211-5218 (1999).	
	J	TAKAHASHI et al., "Immunologic Self-Tolerance Maintained by CD25 <sup>+</sup> CD4 <sup>+</sup> Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte-associated Antigen 4," <i>J. Exp. Med.</i> , Vol. 192, No. 2, pp. 303-309 (July 17, 2000).	

**EXAMINER SIGNATURE:****DATE CONSIDERED:**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Code of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.197 and 1.198. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND PAGES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.